What is NeuroPace?
Founded in 1997, NeuroPace specializes in the design, development, and manufacturing of implantable devices engineered to treat neurological conditions through responsive stimulation. The company's flagship RNS System is a breakthrough in personalized medicine, providing real-time monitoring and intervention for patients with epilepsy. By integrating sophisticated data analytics with neuro-modulation, NeuroPace has carved out a unique niche in the medical technology market, effectively bridging the gap between diagnostic monitoring and therapeutic intervention. Its market position is characterized by high barriers to entry, protected by a robust intellectual property portfolio and deep clinical validation, making it a cornerstone of modern neurological care.
How much funding has NeuroPace raised?
NeuroPace has raised a total of $323.2M across 7 funding rounds:
Private Equity
$49.1M
Private Equity
$18.1M
Series A
$72M
Private Equity
$74M
Debt
$2M
Other Financing Round
$33M
Debt
$75M
Private Equity (2011): $49.1M, investors not publicly disclosed
Private Equity (2013): $18.1M, investors not publicly disclosed
Series A (2016): $72M, investors not publicly disclosed
Private Equity (2017): $74M featuring OrbiMed
Debt (2020): $2M backed by PPP
Other Financing Round (2020): $33M with participation from Revelation Partners, Soleus Capital, KCK Group, Accelmed Partners, and OrbiMed
Debt (2025): $75M led by MidCap Financial
Key Investors in NeuroPace
Revelation Partners
A specialized investment firm providing flexible capital solutions for rapidly growing healthcare companies, with a focus on shareholder liquidity and strategic growth.
OrbiMed
A premier healthcare-focused investment firm managing capital across biopharmaceuticals, medical devices, and digital health, known for its deep operational expertise.
MidCap Financial
A specialized investment corporation providing debt financing and capital solutions to support the operational and growth requirements of established enterprises.
What's next for NeuroPace?
With the recent capital deployment, NeuroPace is well-positioned to accelerate its commercialization efforts and expand the clinical reach of its responsive stimulation platform. The strategic focus will likely shift toward optimizing patient outcomes through enhanced data-driven insights and expanding the accessibility of its devices in both domestic and international markets. Furthermore, the company is expected to leverage its strong balance sheet to pursue operational efficiencies and potential research initiatives that could broaden the application of its neuro-modulation technology to other neurological indications. As the healthcare sector increasingly prioritizes personalized, device-based therapies, NeuroPace remains a key entity to watch for sustained innovation and market leadership.
See full NeuroPace company page
